Seragon Pharmaceuticals Announces Acquisition Agreement With Genentech

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. BAC
2. BHEL:IN
3. TSM
4. BMR
5. ACN
6. BTRMF
7. RKLB
8. VG
9. PAG
10. CTH

Go back to Seragon Pharmaceuticals Announces Acquisition Agreement With Genentech

Genentech (RHHBY) to Acquire Seragon Pharma in ~$1.73B Deal

July 2, 2014 8:00 AM EDT

Genentech, a member of the Roche Group (OTCBB: RHHBY), announced it has entered into a definitive agreement to acquire Seragon Pharmaceuticals, Inc. (Seragon), a privately held biotechnology company based in San Diego, California. With this acquisition, Genentech obtains rights to Seragons entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.

This year, breast cancer will claim the lives of nearly 40,000 women in the United States, and up to half of these women will have a disease that is driven by the estrogen... More